Bionik Laboratories Corp. (BNKL)

Bionik Laboratories Income Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019
Revenue	1.81	1.27	1.19	2.15	3.25
Revenue Growth (YoY)	41.73%	6.73%	-44.58%	-33.66%	228.74%
Cost of Revenue	0.82	0.32	0.27	0.89	1.63
Gross Profit	0.99	0.95	0.92	1.26	1.62
Selling, General & Admin	4.86	4.73	5.53	6.75	6.23
Research & Development	0.9	1	1.54	3.89	3.17
Amortization of Goodwill & Intangibles	-	-	-	-	0.28
Operating Expenses	5.76	5.73	7.08	12.42	11.1
Operating Income	-4.77	-4.77	-6.16	-11.16	-9.49
Interest Expense	-0.11	-0.83	-0.41	-0.18	-3.27
Currency Exchange Gain (Loss)	-	-	-	-	0
Other Non Operating Income (Expenses)	-0.01	-0.11	0.12	0.25	1.86
EBT Excluding Unusual Items	-4.89	-5.71	-6.44	-11.09	-10.89
Merger & Restructuring Charges	-0.05	-	-	-	-
Impairment of Goodwill	-	-4.28	-6.8	-11.22	-
Asset Writedown	-	-0.92	-0.38	-2.7	-
Other Unusual Items	-	0.5	-	-	0.34
Pretax Income	-4.95	-10.41	-13.62	-25.02	-10.56
Net Income	-4.95	-10.41	-13.62	-25.02	-10.56
Net Income to Common	-4.95	-10.41	-13.62	-25.02	-10.56
Shares Outstanding (Basic)	7	6	5	4	2
Shares Outstanding (Diluted)	7	6	5	4	2
Shares Change (YoY)	18.13%	13.95%	15.10%	88.55%	251.02%
EPS (Basic)	-0.72	-1.78	-2.66	-5.61	-4.47
EPS (Diluted)	-0.72	-1.78	-2.66	-5.61	-4.47
Free Cash Flow	-3.4	-4.16	-4.62	-9.22	-9.33
Free Cash Flow Per Share	-0.49	-0.71	-0.90	-2.07	-3.95
Gross Margin	54.84%	74.84%	77.41%	58.51%	49.78%
Operating Margin	-264.40%	-374.70%	-515.76%	-518.45%	-292.28%
Profit Margin	-273.99%	-817.14%	-1141.29%	-1161.75%	-325.21%
Free Cash Flow Margin	-188.12%	-326.59%	-387.44%	-428.32%	-287.56%
EBITDA	-4.71	-4.67	-5.97	-10.78	-9.14
EBITDA Margin	-260.90%	-	-	-	-281.55%
D&A For EBITDA	0.06	0.1	0.19	0.38	0.35
EBIT	-4.77	-4.77	-6.16	-11.16	-9.49
EBIT Margin	-264.40%	-	-	-	-292.28%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.